IPO June 2019 (NASDAQ: AKRO)
Akero Therapeutics is a private company that combines the experience of Big Pharma with a nimble, capital-efficient, biotech ethos to create medicines designed to transform the lives of people living with serious metabolic diseases. We are committed to developing best-in-class therapies for metabolic diseases with limited or no treatment options.
Aligos Therapeutics is a privately held biotechnology company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases. Aligos is focused on the development of targeted therapies for hepatologic diseases and viral infections.
ArTara Therapeutics is a privately held rare and specialty diseases therapeutics company focused on identifying and optimizing product candidates for patients suffering from diseases where there is a significant unmet need. ArTara’s current development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders.
IPO June 2019 (NASDAQ: BCEL)
Atreca is a private company developing novel therapeutics based on a deep understanding of the human immune response. They focus in a unique way on the immune responses of patients in therapeutic areas where such responses are the key phenomenon driving clinical outcomes, enabling us to discover and develop novel immunotherapies, including those in our lead programs in oncology.
Attune Pharmaceuticals is a private biotechnology company focused on discovering and developing novel orally-administered small-molecule therapeutics for the treatment of rare diseases.
IPO February 2016 – Acquisition April 2018
AveXis was a clinical-stage gene therapy company relentlessly focused on bringing gene therapy out of the lab and into the clinical setting for patients and families devastated by rare and orphan neurological genetic diseases.
Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines – Antibody-siRNA Conjugates (ASC™) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics to overcome barriers to the delivery of siRNA and target genetic drivers of disease.
IPO February 2016 (NASDAQ: BGNE)
BeiGene is a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies.
IPO April 2015 (NASDAQ: BPMC)
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases.
Boundless Bio is a biopharmaceutical company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.
IPO October 2019 – (NASDAQ: CABA)
Cabaletta Bio is a private company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health.
CiVi Biopharma Inc. is a US-based, privately held biopharmaceutical company, founded in 2016. The company’s research and development activities are focused on creating novel therapies against cardiovascular and metabolic diseases.
Codiak is building a unique platform to employ exosomes as therapeutics. At Codiak, we can engineer specific messages into the exosome system, effectively hijacking their biology to define a new class of medicines.
IPO February 2007 – Acquisition May 2009
Cougar Biotechnology was a development stage biopharmaceutical company with a specific focus on oncology.
Encoded Therapeutics is a private company whose mission is to realize the potential of genomics-driven precision medicine by overcoming key limitations of viral gene therapy.
IPO May 2017 (NASDAQ: GTHX)
G1 Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule therapies to address significant unmet needs in oncology. The company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of first-in-class compounds and best-in-class drug candidates in multiple oncology indications.
IPO May 2019 (NASDAQ: IDYA)
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity. IDEAYA, headquartered in South San Francisco, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology, immunology, and small molecule drug discovery.
IPO May 2018 (NASDAQ: KNSA)
Kiniksa is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.
IPO May 2019 (NASDAQ: MIST)
Milestone Pharmaceuticals is a patient-centric, clinical-stage biopharmaceutical company dedicated to bringing etripamil to patients living with PSVT or other episodic cardiovascular conditions.
Redomiciled to San Diego, CA – 2013 (NASDAQ: MRTX)
Mirati Therapeutics is a targeted oncology company developing breakthrough medicines for precisely defined patient populations.
Nuvation Bio is a biotechnology company focusing on the foremost unmet needs in oncology.
IPO December 2017 (NASDAQ: ODT)
Odonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer.
Passage Bio is a genetic medicines company developing therapies for the treatment of rare monogenic central nervous system diseases.
PMV Pharma is developing first-in-class p53 regulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics.
IPO June 2019 (NASDAQ: PRVL)
Prevail Therapeutics is developing therapeutics for neurodegenerative diseases.
Relay Therapeutics is a private company that was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities.
Revolution Medicines is a private company that discovers and develops important new medicines for cancer patients by translating frontier oncology targets—proteins that drive the growth of cancers or that control immune responses that can defeat them.
Reverse Merger – January 2018 (NASDAQ: RCKT)
Bringing hope and relief to patients with undertreated rare diseases through the development and commercialization of curative first-in-class gene therapies.
Sojournix is a biotechnology company developing innovative medicines for women’s health and endocrine disorders.
IPO September 2019 (NASDAQ: SWTX)
SpringWorks Therapeutics is a private clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways for drug development for patients with severe rare diseases and cancer.
IPO March 2016 (NASDAQ: SNDX)
Syndax is determined to realize a future in which people with cancer live longer and better than ever before. Syndax is currently focused on developing an innovative pipeline of combination therapies in multiple cancer indications.
Tyra Biosciences aspires to be a leading oncology company leveraging the promise of new biology and emerging technology to deliver targeted therapies to cancer patients.